193 related articles for article (PubMed ID: 17307357)
1. Predicting anti-HIV activity of PETT derivatives: CoMFA approach.
Ravichandran V; Agrawal RK
Bioorg Med Chem Lett; 2007 Apr; 17(8):2197-202. PubMed ID: 17307357
[TBL] [Abstract][Full Text] [Related]
2. Predicting anti-HIV activity of 1,3,4-thiazolidinone derivatives: 3D-QSAR approach.
Ravichandran V; Prashantha Kumar BR; Sankar S; Agrawal RK
Eur J Med Chem; 2009 Mar; 44(3):1180-7. PubMed ID: 18687505
[TBL] [Abstract][Full Text] [Related]
3. CoMFA 3D-QSAR analysis of HIV-1 RT nonnucleoside inhibitors, TIBO derivatives based on docking conformation and alignment.
Zhou Z; Madura JD
J Chem Inf Comput Sci; 2004; 44(6):2167-78. PubMed ID: 15554687
[TBL] [Abstract][Full Text] [Related]
4. 3D-QSAR CoMFA of a series of DABO derivatives as HIV-1 reverse transcriptase non-nucleoside inhibitors.
de Brito MA; Rodrigues CR; Cirino JJ; de Alencastro RB; Castro HC; Albuquerque MG
J Chem Inf Model; 2008 Aug; 48(8):1706-15. PubMed ID: 18671385
[TBL] [Abstract][Full Text] [Related]
5. Effect of stereo and regiochemistry towards wild and multidrug resistant HIV-1 virus: viral potency of chiral PETT derivatives.
Venkatachalam TK; Mao C; Uckun FM
Biochem Pharmacol; 2004 May; 67(10):1933-46. PubMed ID: 15130770
[TBL] [Abstract][Full Text] [Related]
6. Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity relationship studies of PETT analogs.
Cantrell AS; Engelhardt P; Högberg M; Jaskunas SR; Johansson NG; Jordan CL; Kangasmetsä J; Kinnick MD; Lind P; Morin JM; Muesing MA; Noreén R; Oberg B; Pranc P; Sahlberg C; Ternansky RJ; Vasileff RT; Vrang L; West SJ; Zhang H
J Med Chem; 1996 Oct; 39(21):4261-74. PubMed ID: 8863804
[TBL] [Abstract][Full Text] [Related]
7. CoMFA and CoMSIA studies on thiazolidin-4-one as anti-HIV-1 agents.
Murugesan V; Prabhakar YS; Katti SB
J Mol Graph Model; 2009 Feb; 27(6):735-43. PubMed ID: 19117780
[TBL] [Abstract][Full Text] [Related]
8. QSAR study of PETT derivatives as potent HIV-1 reverse transcriptase inhibitors.
Sabet R; Fassihi A; Moeinifard B
J Mol Graph Model; 2009 Sep; 28(2):146-55. PubMed ID: 19570701
[TBL] [Abstract][Full Text] [Related]
9. 3D-QSAR models on clinically relevant K103N mutant HIV-1 reverse transcriptase obtained from two strategic considerations.
San Juan AA
Bioorg Med Chem Lett; 2008 Feb; 18(3):1181-94. PubMed ID: 18155520
[TBL] [Abstract][Full Text] [Related]
10. 3D-QSAR and docking studies on the HEPT derivatives of HIV-1 reverse transcriptase.
Latha RS; Vijayaraj R; Singam ER; Chitra K; Subramanian V
Chem Biol Drug Des; 2011 Sep; 78(3):418-26. PubMed ID: 21689378
[TBL] [Abstract][Full Text] [Related]
11. Effect of stereochemistry on the anti-HIV activity of chiral thiourea compounds.
Venkatachalam TK; Mao C; Uckun FM
Bioorg Med Chem; 2004 Aug; 12(15):4275-84. PubMed ID: 15246104
[TBL] [Abstract][Full Text] [Related]
12. 2-(Aryl)-3-furan-2-ylmethyl-thiazolidin-4-ones as selective HIV-RT inhibitors.
Rawal RK; Prabhakar YS; Katti SB; De Clercq E
Bioorg Med Chem; 2005 Dec; 13(24):6771-6. PubMed ID: 16198576
[TBL] [Abstract][Full Text] [Related]
13. Dawn of non-nucleoside inhibitor-based anti-HIV microbicides.
D'Cruz OJ; Uckun FM
J Antimicrob Chemother; 2006 Mar; 57(3):411-23. PubMed ID: 16431862
[TBL] [Abstract][Full Text] [Related]
14. [The use of complex interval models for predicting activity of non-nucleoside reverse transcriptase activity].
Burliaeva EV; Tarkhov AE; Burliaev VV; Iurkevich AM; Shvets VI
Vopr Med Khim; 2002; 48(2):219-30. PubMed ID: 12189631
[TBL] [Abstract][Full Text] [Related]
15. Three-dimensional quantitative structure-activity relationship study on cyclic urea derivatives as HIV-1 protease inhibitors: application of comparative molecular field analysis.
Debnath AK
J Med Chem; 1999 Jan; 42(2):249-59. PubMed ID: 9925730
[TBL] [Abstract][Full Text] [Related]
16. 3D-QSAR studies of farnesyltransferase inhibitors: a comparative molecular field analysis approach.
Puntambekar D; Giridhar R; Yadav MR
Bioorg Med Chem Lett; 2006 Apr; 16(7):1821-7. PubMed ID: 16455255
[TBL] [Abstract][Full Text] [Related]
17. Computer-aided molecular design of highly potent HIV-1 RT inhibitors: 3D QSAR and molecular docking studies of efavirenz derivatives.
Pungpo P; Saparpakorn P; Wolschann P; Hannongbua S
SAR QSAR Environ Res; 2006 Aug; 17(4):353-70. PubMed ID: 16920659
[TBL] [Abstract][Full Text] [Related]
18. GRID formalism for the comparative molecular surface analysis: application to the CoMFA benchmark steroids, azo dyes, and HEPT derivatives.
Polanski J; Gieleciak R; Magdziarz T; Bak A
J Chem Inf Comput Sci; 2004; 44(4):1423-35. PubMed ID: 15272850
[TBL] [Abstract][Full Text] [Related]
19. 3D QSAR CoMFA/CoMSIA, molecular docking and molecular dynamics studies of fullerene-based HIV-1 PR inhibitors.
Durdagi S; Mavromoustakos T; Papadopoulos MG
Bioorg Med Chem Lett; 2008 Dec; 18(23):6283-9. PubMed ID: 18951793
[TBL] [Abstract][Full Text] [Related]
20. Neural networks: Accurate nonlinear QSAR model for HEPT derivatives.
Douali L; Villemin D; Cherqaoui D
J Chem Inf Comput Sci; 2003; 43(4):1200-7. PubMed ID: 12870912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
